◎ Sugi Atlas

Atlas / Drug / Porfimer Sodium

Porfimer Sodium

drug
On this page

Also known as CL 184,116CL-184,116CL-184116PhotobarrPhotofrinPhotofrin iiPorfimere sodiquePorfimero de sodioProfimer sodiumphotofrin(R)haemaporphyrin

Summary

Porfimer Sodium (CHEMBL1201481) is an approved small molecule (ATC L01XD01); indicated across 18 conditions including neoplasm and barrett esophagus.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XD01
  • Indications: 18 conditions
  • Clinical trials: 25

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201481
NamePorfimer Sodium
TypeSmall molecule
Max phase4
ATCL01XD01

Also known as: CL 184,116, CL-184,116, CL-184116, Photobarr, Photofrin, Photofrin ii, Porfimer sodium, Porfimere sodique, Porfimero de sodio, Profimer sodium, photofrin(R), haemaporphyrin

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

18 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
Barrett esophagus4MONDO:0013662EFO:0000280
hilar cholangiocarcinoma3MONDO:0003345EFO:1001959
central nervous system neoplasm3MONDO:0006130EFO:1000158
bile duct carcinoma3MONDO:0005496EFO:0005540
gallbladder neoplasm3MONDO:0021253MONDO:0005411
malignant pleural mesothelioma2MONDO:0005112EFO:0000770
brain neoplasm2MONDO:0021211EFO:0003833
mesothelioma2MONDO:0005065EFO:0000588
head and neck cancer2MONDO:0005627EFO:0006859
lung neoplasm2MONDO:0021117MONDO:0008903
lung carcinoma2MONDO:0005138EFO:0001071
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
small cell lung carcinoma1MONDO:0008433EFO:0000702

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

PhaseTrials
PHASE28
PHASE16
PHASE34
Not specified4
PHASE1/PHASE22
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00003788PHASE3UNKNOWNSurgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
NCT00118222PHASE3COMPLETEDHigh Light and Low Light Dose PDT in Glioma
NCT00253617PHASE3WITHDRAWNStent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
NCT00513539PHASE3COMPLETEDBiliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
NCT02153229PHASE2ACTIVE_NOT_RECRUITINGPhase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
NCT00002935PHASE2COMPLETEDPhotodynamic Therapy in Treating Patients With Early Esophageal Cancer
NCT00002964PHASE2COMPLETEDPorfimer Sodium in Diagnosing Patients With Head and Neck Cancer
NCT00003923PHASE2COMPLETEDPhotodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
NCT00054002PHASE2COMPLETEDSurgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
NCT00322699PHASE1/PHASE2COMPLETEDSequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
NCT00453336PHASE2COMPLETEDPhotodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
NCT00601848PHASE2TERMINATEDPhotodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
NCT02068157PHASE2TERMINATEDInterstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT03735095PHASE1/PHASE2COMPLETEDEndobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
NCT01770132PHASE1COMPLETEDUltrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
NCT02916745PHASE1COMPLETEDFeasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
NCT03344861PHASE1COMPLETEDSafety of PDT-Photofrin® Prior to Lung Surgery
NCT03678350PHASE1COMPLETEDLight Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
NCT03727061PHASE1TERMINATEDPorfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
NCT04836429PHASE1TERMINATEDPhotodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease
NCT04753918EARLY_PHASE1UNKNOWNNovel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study
NCT00530088Not specifiedTERMINATEDPhotodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
NCT00754910Not specifiedCOMPLETEDPhotodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease
NCT01506115Not specifiedCOMPLETEDSafety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma
NCT02106559Not specifiedWITHDRAWNPhotodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 14

This page pulls from 14 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem